Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib - Promius Pharma

Next Previous
Search
Drug Profile

Celecoxib - Promius Pharma

Alternative Names: DFN-15; DFN-15A; DFN-15B; ELYXYB

Latest Information Update: 30 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Promius Pharma
  • Developer BioDelivery Sciences International; Scilex Holding
  • Class Antimigraines; Antineoplastics; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine
  • Phase II Postoperative pain

Most Recent Events

  • 22 Jan 2025 Scilex Holding files Supplemental New Drug Application (SNDA) to the US FDA for Acute pain, before January 2025
  • 21 Jan 2025 Scilex Holding announces intention to file Supplemental New Drug Application (SNDA) to the US FDA for Acute pain indication
  • 16 Oct 2024 Scilex Holding anticipates approval of Celecoxib for Migraine in Canada in first quarter of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top